The renewed debate over Most Favored Nation (MFN) drug pricing in the United States reflects a legitimate frustration: ...

Generic medicines face no tariffs, though the Trump administration reserves the right to revisit that in the future. Some branded drugmakers face a reduced tariff rate, but that could change if they ...

The Trump administration released its 2026 Economic Report this week, outlining achievements from the past year and goals for ...

The new U.S.-U.K. pharmaceutical agreement is an important reminder that there is a smarter way to address global ...

When the Trump administration announced its Most Favored Nation policy, it was portrayed as a simple, sensible idea. Drug ...

Pharmaceutical research and development (R&D) is unlikely to be significantly impacted by most favored nation (MFN) pricing, according to industry experts. The US bears the highest drug costs globally ...

Forbes contributors publish independent expert analyses and insights. Sally Pipes is a scholar and think tank CEO who writes on health care. "MFN reinforces the worst incentives in 340B, shifts costs ...

Earlier this year, when the administration proposed deep cuts to the National Institutes of Health, lawmakers from both parties swiftly and rightly pushed back. Slashing medical research funding, they ...

MFN policies are likely to impact more than pricing, and drug companies may alter drug launch plans in the future. With the launch of TrumpRx earlier this year, Americans got their first taste of how ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...